Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR1020-CD8 in KRAS-mutated cancers
NCT06707896Phase 1Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jun 2025
- Primary completion
- Feb 2029
- Modality
- TCR-Engineered T Cells
01
Overview
Phase 1, open-label trial of TCR1020-CD8 in pancreatic adenocarcinoma (PDAC) and metastatic colorectal cancer (mCRC) (4 arms), sponsored by University of Pennsylvania. Primary endpoints: Number of Subjects with dose limiting toxicities at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Planned start Jun 2025; status: withdrawn.
02
Drugs
TCR1020-CD8
03
Conditions
pancreatic adenocarcinoma (PDAC)metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06707896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707896.